* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download AIDS Vaccines: The basics - View the full AIDS 2016 programme
Survey
Document related concepts
Adoptive cell transfer wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Adaptive immune system wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Innate immune system wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Globalization and disease wikipedia , lookup
DNA vaccination wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Vaccination wikipedia , lookup
Transcript
AVAC Global Advocacy for HIV Prevention HIV Vaccines: The basics May 2016 Presentation Overview • • • • What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a vaccine? • A substance that teaches the immune system how to protect itself against a virus or bacteria • No effective HIV vaccine available today • HIV vaccines cannot cause HIV • No vaccine is 100% effective • Most vaccines licensed in the US 70%-95% effective Why the interest in HIV vaccines? • Proven prevention options have slowed HIV’s spread – but thousands of people continue to get infected daily • There is a need for a range of HIV prevention methods; there is no silver bullet • Vaccines are one of the world’s most effective public health tools • Cost-effective – single or several doses likely provide protection for years How vaccines are crucial to ending HIV Types of HIV vaccines • Preventive vaccines – Designed for people who are not infected with HIV – If effective, would reduce risk of infection – May also reduce viral load set point after infection • Therapeutic vaccines – Designed for people who are living with HIV – If effective, would use the body’s immune system to help control or clear HIV in the body How do preventive vaccines work? By teaching the body to recognize and fight a pathogen • Vaccine carries something that ‘looks and feels’ like the pathogen, but is not really the pathogen • Body reacts by creating antibodies or killer cells and a memory response • Upon exposure to the ‘real’ pathogen, antibodies and killer cells are waiting to respond and attack Note: This is a general definition, not specific to HIV vaccines How might preventive HIV vaccine work? A preventive vaccine would teach the body to recognize and fight HIV, should it be exposed • Vaccine would carry a component that ‘looks and feels’ like HIV, but is not HIV and cannot cause HIV infection • Component might be a synthetic fragment of HIV known to generate an immune response • Body would react by creating antibodies and/or killer cells and a memory response • Upon possible exposure to HIV, antibodies and killer cells would be waiting to prevent and/or control infection Immune responses Preventive HIV vaccines are meant to elicit two arms of the immune system – humoral and cellular (1) Humoral immunity • Primary action of humoral arm is creating antibodies • Antibodies are Y-shaped proteins developed in response to a pathogen to prevent infection Immune responses Preventive HIV vaccines are meant to elicit two arms of the immune system – humoral and cellular (2) Cellular immunity • Cytotoxic T lymphocytes and Thelper cells • Cells recognize HIVinfected cells and kill them Preventing vs. controlling infection HIV PREVENT ESTABLISHED INFECTION? ***** C A Vaccine Administered B HAART A. Lower Initial Peak of Viremia B. Lower Set Point Courtesy of HIV Vaccine Trials Network C. Delay Progression How have many vaccines been made? • Live attenuated vaccines (examples: measles, mumps, and rubella) • Whole killed virus vaccines (example: influenza and rabies) How are HIV vaccines made? Recombinant vaccines • DNA vaccines • Vector vaccines • Subunit vaccines Do not contain HIV – only synthetic copies of fragments of HIV that will create an immune response but do not cause HIV infection Developing an HIV vaccine is difficult • Numerous modes of transmission • HIV kills the very immune cells used in defending the body against HIV • HIV makes many copies of itself and mutates, making itself unrecognizable to the immune system • Mutation leads to different subtypes of the virus throughout the world Vaccine research in history Duration between discovery of microbiologic cause of selected infectious diseases and development of a vaccine Virus or bacteria Year cause discovered Year vaccine licensed Years elapsed Typhoid 1884 1989 105 Haemophilus Influenzae 1889 1981 92 Malaria 1893 None – Pertussis 1906 1995 89 Polio 1908 1955 47 Measles 1953 1995 42 Hepatitis B 1965 1981 16 Rotavirus 1973 1998 25 HPV 1974 2007 33 HIV 1983 None – Source: AIDS Vaccine Handbook, AVAC, 2005 HIV vaccine efficacy trial results YEAR PRODUCT/ CLADE/ TRIAL NAME LOCATION # RESULT 2003 AIDSVAX B/B VAX003 Canada, Netherlands, Puerto Rico, US 5,417 No effect 2003 AIDSVAX B/E VAX004 Thailand 2,546 No effect 2007 MRK-Ad5 B Step Australia, Brazil, Canada, Dominican Republic, Haiti, Jamaica, Peru, Puerto Rico, US 3,000 Immunizations halted early for futility; subsequent data analysis found potential for increased risk of HIV infection among Ad5seropositive, uncircumcised men. 2007 MRK-Ad5 B Phambili South Africa 2009 ALVAC-HIV (vCP1521) and AIDSVAX B/E Thai Prime-Boost/RV 144 Thailand 2013 DNA and Ad5 A/B/C HVTN 505 US 801 Immunizations halted based on Step result. 16,402 Modest effect (31.2%) 2,500 Immunizations halted early for futility; vaccine regimen did not prevent HIV infection nor reduce viral load among vaccine recipients who became www.avac.org/presentations infected with HIV; follow-up continues. Pox-Protein strategies • In 2009 clinical study in Thailand (‘RV144’) showed evidence that a vaccine can reduce HIV risk – Pox-protein, prime-boost regimen using canary pox (ALVAC) and manufactured HIV protein-GP120 – Moderately effective – 31% protection; not licensable – Follow up research identified possible explanations for vaccinerelated protection and avenues for improvement • New clinical trials launched by P5 in southern Africa in January 2015 – Modified regimen being tested in South Africa; potential efficacy trial that might lead to licensure could start in late 2016 – Other regimens being tested for proof-of-concept, improved responses More information about Rv144 and the follow-up at: http://hivresearch.org/research.php?ServiceID=13 Antibody research • 100s of broadly neutralizing antibodies (bNAbs) identified since 2009 – Work against majority of HIV strains – Target limited number of sites on HIV surface • Direct transfer of antibodies—passive immunization—being tested as prevention, treatment, part of cure – Multiple bNAbs tested in early clinical trials: www.bnaber.org – Many show safety, tolerability, significant viral reduction among HIVpositive participants – First large-scale study of bNAb VRC01 initiated April 2016 for proof of concept, called AMP study: www.ampstudy.org – Hope to increase potency of bNAbs, duration of responses – Possible alternate delivery mechanisms to infusion, e.g. series of subcutaneous shots – Possible future combination bNAb approaches Antibody research Future priorities • P5 – large-scale trials following RV144 results in South Africa, possibly Thailand • Janssen-sponsored product and clinical testing of ‘mosaic’ (cross-clade) based strategy • Implications of AMP Study results for future of bNAb research and vaccine design • Advancement of candidates/strategies in smaller-scale trial • Pre-clinical discovery and advancement of individual bNAbs and combinations in clinical trials • Continued identification of novel vectors, adjuvants and other strategies for improved candidates Advocates’ checklist • Monitor timelines of clinical trials, especially delays and the reasons for them • Ensure diversity of approaches beyond pox-protein strategy, exploring novel directions for vaccine design • Push for more stakeholder involvement, e.g., on trial design, standard of prevention/care, decisionmaking on moving candidates through the clinical pipeline Key resources • AVAC: www.avac.org/vaccines • Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) o At Duke: www.chavi-id-duke.org o At Scripps: www.cavi-id.org • Collaboration for AIDS Vaccine Discovery: www.cavd.org • Global HIV Vaccine Enterprise: www.vaccineenterprise.org • HIV Px R&D Database (PxRD): www.data.avac.org • HIV Vaccines & Microbicides Resource Tracking Working Group: www.hivresourcetracking.org • HIV Vaccine Trials Network (HVTN): www.hvtn.org • International AIDS Vaccine Initiative (IAVI): www.iavi.org • Military HIV Research Program (MHRP): www.hivresearch.org • NIAID: www.niaid.nih.gov/topics/hivaids/research/vaccines/Pages/default.aspx • NIH Vaccine Research Center (VRC): www.vrc.nih.gov • Pox-Protein Public-Private Partnership (P5): www.hivresearch.org/media/pnc/9/media.749.pdf Connect With Us • Questions, comments and requests for materials should be sent to [email protected] • For the latest news and updates, sign up for our Advocates’ Network mailing list at www.avac.org/signup or follow us on Facebook at www.facebook.com/hivpxresearch and on Twitter at www.twitter.com/hivpxresearch The Basics of HIV Cure Research HIV Cure Research Training Curriculum HIV and Cure Basics Module Presented by Jessica Salzwedel: July 2016 The HIV CURE research training curriculum is a collaborative project aimed at making HIV cure research science accessible to the community and the HIV research field. Objectives Describe: ●Different ways to conceptualize an HIV cure ●Why it is difficult to cure HIV ●Rationale for exploring a cure ●Current cure strategies being researched What is an HIV Cure? What Does HIV Cure Mean? What Does HIV Cure Mean? ●No need for on-going medication (ARV treatment) ●No symptoms ●No viral progression/immune damage ●No risk of transmission The Language of “Cure” ● Sterilizing/Eradication● HIV is completely removed from every cell in the body ● Person is HIV-free (virus free) ● Functional/Remission● HIV is NOT completely gone from the body ● All requirements from previous slide met ● HIV has potential to resurface. What is an HIV Cure? Why is it so Hard to Cure HIV? Why is HIV so Hard to Cure? ●HIV enters a cell and integrates into the cell’s DNA ●Most cells recognize infection- causing cell death ●A few infected cells become “long-lived” memory cells or “resting memory” cells ●The collection of long-lived memory cells is called the Latent Reservoir Why is HIV so Hard to Cure? Why is it so Hard to Cure HIV: Establishing the Latent Reservoir HIV Latent Reservoir Naïve CD4+ T cell Cell Death Activated CD4+ T cell Cell Survival Resting Memory CD4+ T cell Adapted from D. Persaud Why is it so Hard to Cure HIV: Establishing the Latent Reservoir Latent Reservoir Reactivated CD4+ T cell Adapted from D. Persaud Where is the HIV Reservoir? ● Brain ● Lymph nodes ● Peripheral blood ● Gut ● Bone marrow ● Genital tract Adapted from A. Fauci How Can the Reservoir be Measured? ●Reservoir size varies from person to person. Different factors, like genetics, when ART was initiated, and viral load during exposurewill influence reservoir size ●Obtaining samples from some tissues (e.g. spleen, brain) can be difficult because of location ●Currently, there is no standard test that accurately measures the reservoir How Can the Reservoir be Measured? HIV DNA Intact VOA Scale=100/106 Ho et al, Cell, 2013 Why is an HIV Cure Important? ●Disparity of access to care/HIV treatment globally ●Medication burden ●Medication side effects ●Expense HIV Cure: Proof of Concept ● HIV+ Acute Myeloid Leukemia Patient ● Identification of HLA-identical, CCR5Δ32 homozygous bone marrow donor ● Chemo- and Radiotherapy Conditioning ● Allogeneic stem cell transplant ● 7 years later: remains cured What are the Research Stages? Basic science Translational research Clinical (human) trials Basic research Preclinical research Concept studies Phase I Smaller safety studies Phase II Larger, longer look at safety and immunogenicity Phase IIb Lab studies Even larger look at safety and efficacy Animal studies Even larger look at safety and efficacy Posteffectiveness Post licensure activities vary with each product/intervention Demonstration Project Phase IV Marketing studies Product introduction Phase III Open-label extension (OLE)/Post-trial access Safety and efficacy Real-world effectiveness Population scale-up Often a product /intervention does not progress in a linear fashion License What is an HIV Cure? Current Strategies What is an HIV Cure? Kick and Kill or Shock and Kill Kick and Kill The Economist, July 17, 2011 What is Kick and Kill ●A two step approach that: ● Stimulates virus production from latent cells ● Kills virus particles outside the cell and infected cells What is kick and kill? LRA Cell death Latency Reversing Agents ●A category of drugs that stimulate HIV-positive long-lived memory cells to begin producing virus ●HDAC InhibitorsHistone Deacetylase Inhibitors have been one of the class of drugs being pursued in the field Notable LRAs • TLR7- Agonist • Bromodomain Inhibitors • Ingenol What is an HDAC Inhibitor? Current Challenges of Kick and Kill ●Measurement of reservoir size/Getting it all ●New reservoirs ●Medication side effects What is an HIV Cure? Immune Modulation What are Immune Modulators? ●Category of research that harnesses the innate and adaptive immune system to better recognize and/or fight HIV ●All immune modulators would likely need to be used in combination with each other or other approaches Innate immunity- No specific response; first line of defense like skin Adaptive immunityTargeted responses to specific pathogenscreating a whole army dedicated to attacking one enemy How the Immune System Works HVTN “Soldiers” of the Immune System Therapeutic Vaccines ●Rationale: Strengthen or create new and more effective immune responses to HIV in people living with HIV ●Generate long-lived adaptive immune responses to HIV that can continue to control the virus without medication Broadly Neutralizing Antibodies ●Broadly Neutralizing Antibodies (bNAbs) are able to make many different mutations of HIV harmless by binding to 1 of 3 places on HIV ●bNAbs are currently being explored for use in HIV prevention, treatment and cure Current Challenges of Immune Modulation ●Complex regulatory issues because each vaccine component will need to be evaluated separately and in combination ●Animal models do not always translate to humans ●Proving that strict immune control of HIV is clinically equivalent or better than ART What is an HIV Cure? Gene Alteration/Modification What is Gene Alteration/Modification? ●A process to edit the DNA inside immune cells in some way to make the cell less susceptible to HIV ●A process to edit the DNA inside immune cells to increase the killing potential of the cells ●A process to edit the DNA inside the virus to reduce it’s ability to impact people What is Gene Alteration/Modification Creating HIV Immunity ● HIV needs a receptor, CCR5, to be present on a cell surface in order to enter the cell and cause damage ● One focus of gene therapy in Other Tools Used • CRISPR/Cas9 trials is to remove or block this • receptor ● Zinc Fingers, molecular scissors used to edit genes, are one of the main tools being explored in clinical research Mega Tals • TAL Effector Nucleases Creating HIV Immunity Virus-Mediated Transfer of Mobilization Therapeutic Gene Leukapheresis OR Bone Marrow Harvest Isolation of Stem Cells or T cells Reinfusion Patient Challenges to Gene Alteration/Modification ●Assuring only on-target modifications made ●Unknown how much modification is needed to produce benefit (therapeutic threshold) ●Development of potential immunity to the tools used to make gene alterations occur ●Current cost and scalability What is an HIV Cure? Ethical Challenges What Are the Social & Ethical Challenges ●Balancing resources ●Risk versus reward ●Participant selection ●Trial design ●Cost ●Scalability What Does an HIV Cure Need to Be? ●Safe ●Effective ●Durable ●Affordable ●Accessible Questions For additional information visit: www.avac.org/CUREiculum Acknowledgements